Drugs & Targets FDA grants priority review to capivasertib + Faslodex for advanced HR-positive breast cancer June 16, 2023Vol.49 No.24
Drugs & Targets FDA accepts sBLA for Keytruda in combination with chemotherapy in liver cancer indication June 09, 2023Vol.49 No.23
Drugs & Targets FDA approves BMS cell-manufacturing facility in Massachusetts June 09, 2023Vol.49 No.23
Drugs & Targets FDA approves Lynparza with abiraterone, prednisone (or prednisolone) for BRCA-mutated metastatic castration-resistant prostate cancer June 02, 2023Vol.49 No.22
Drugs & Targets FDA approves Posluma—first radiohybrid PSMA-targeted PET imaging agent for prostate cancer June 02, 2023Vol.49 No.22
Drugs & Targets FDA grants priority review to repotrectinib for locally advanced or metastatic ROS1-positive NSCLC June 02, 2023Vol.49 No.22
Drugs & Targets EMA CHMP recommends approval of Opdivo + chemo for the neoadjuvant treatment of PD-L1 positive, resectable NSCLC at a high risk of recurrence June 02, 2023Vol.49 No.22
Drugs & Targets Lifebit, Flatiron Health partner to accelerate cancer data research June 02, 2023Vol.49 No.22
Drugs & Targets Leal Health establishes proprietary platform for oncologists to obtain personalized clinical trial matches for patients June 02, 2023Vol.49 No.22
Drugs & Targets FDA grants accelerated approval to Epkinly for R/R DLBCL and high-grade B-cell lymphoma May 26, 2023Vol.49 No.21
